Literature DB >> 33563576

HLA-G/LILRBs: A Cancer Immunotherapy Challenge.

Edgardo D Carosella1, Silvia Gregori2, Diana Tronik-Le Roux3.   

Abstract

Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA-G; LILRB1/2; cancer immunotherapy; immune checkpoints; vascular endothelial growth factor; vascular targeting

Mesh：

Substances：

Year:  2021        PMID： 33563576     DOI： 10.1016/j.trecan.2021.01.004

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  8 in total

1.  Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells.

Authors:  Hana Rohn; Cordula Lang; Sabine Schramm; Falko M Heinemann; Mirko Trilling; Anja Gäckler; Oliver Witzke; Peter A Horn; Vera Rebmann
Journal:  J Immunol Res       Date:  2022-05-12       Impact factor: 4.493

2.  Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.

Authors:  Qiong-Yuan Chen; Yu-Xin Chen; Qiu-Yue Han; Jiang-Gang Zhang; Wen-Jun Zhou; Xia Zhang; Yao-Han Ye; Wei-Hua Yan; Aifen Lin
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

3.  HLA-G 3'UTR Polymorphisms Are Linked to Susceptibility and Survival in Spanish Gastric Adenocarcinoma Patients.

Authors:  Christian Vaquero-Yuste; Ignacio Juarez; Marta Molina-Alejandre; Elisa María Molanes-López; Adrián López-Nares; Fabio Suárez-Trujillo; Alberto Gutiérrez-Calvo; Adela López-García; Inmaculada Lasa; Remedios Gómez; Eduardo Fernández-Cruz; Carmen Rodrígez-Sainz; Antonio Arnaiz-Villena; José Manuel Martín-Villa
Journal:  Front Immunol       Date:  2021-09-07       Impact factor: 7.561

Review 4.  The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.

Authors:  Simon Jasinski-Bergner; Markus Eckstein; Helge Taubert; Sven Wach; Christian Fiebig; Reiner Strick; Arndt Hartmann; Barbara Seliger
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

Review 5.  HLA-G and single nucleotide polymorphism (SNP) associations with cancer in African populations: Implications in personal medicine.

Authors:  Ismael Chatita Adolf; Amany Almars; Nazima Dharsee; Teddy Mselle; Gokce Akan; Irene Jeremiah Nguma; Abdolrahman S Nateri; Fatmahan Atalar
Journal:  Genes Dis       Date:  2021-06-30

6.  BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.

Authors:  Ilana Mandel; Dana Haves Ziv; Ilana Goldshtein; Tsuri Peretz; Dror Alishekevitz; Anna Fridman Dror; Motti Hakim; Sharon Hashmueli; Itay Friedman; Yair Sapir; Rita Greco; Hongjing Qu; Frank Nestle; Dmitri Wiederschain; Lily Pao; Sharad Sharma; Tehila Ben Moshe
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 7.  Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.

Authors:  Katrin Pansy; Barbara Uhl; Jelena Krstic; Marta Szmyra; Karoline Fechter; Ana Santiso; Lea Thüminger; Hildegard Greinix; Julia Kargl; Katharina Prochazka; Julia Feichtinger; Alexander Ja Deutsch
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 8.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.